369 related articles for article (PubMed ID: 9023706)
1. Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovir-resistant HSV in mice.
Yoshida Y; Yamamura J; Sato H; Koyasu M; Obara Y; Sekiguchi H; Kawana T; Shiraki K
J Dermatol Sci; 1996 Dec; 13(3):237-41. PubMed ID: 9023706
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of cutaneous herpes simplex virus-1 infection in mice with a specially formulated caffeine gel (Cafon).
Yamamura J; Koyasu M; Sato H; Kurokawa M; Yoshida Y; Amahabu Y; Shiraki K
J Dermatol Sci; 1996 Apr; 12(1):50-5. PubMed ID: 8740461
[TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice.
Park HJ; Kurokawa M; Shiraki K; Nakamura N; Choi JS; Hattori M
Biol Pharm Bull; 2005 Dec; 28(12):2258-62. PubMed ID: 16327161
[TBL] [Abstract][Full Text] [Related]
4. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
Okuda T; Kurokawa M; Matsuo K; Honda M; Niimura M; Shiraki K
J Med Virol; 2004 Jan; 72(1):112-20. PubMed ID: 14635018
[TBL] [Abstract][Full Text] [Related]
5. Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
Kurokawa M; Hozumi T; Tsurita M; Kadota S; Namba T; Shiraki K
J Pharmacol Exp Ther; 2001 Apr; 297(1):372-9. PubMed ID: 11259565
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus resistance to acyclovir: clinical relevance.
Pottage JC; Kessler HA
Infect Agents Dis; 1995 Sep; 4(3):115-24. PubMed ID: 8548189
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of A-73209, a potent orally active agent against VZV and HSV infections.
Alder J; Mitten M; Norbeck D; Marsh K; Kern ER; Clement J
Antiviral Res; 1994 Feb; 23(2):93-105. PubMed ID: 8147583
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.
Gaudreau A; Hill E; Balfour HH; Erice A; Boivin G
J Infect Dis; 1998 Aug; 178(2):297-303. PubMed ID: 9697707
[TBL] [Abstract][Full Text] [Related]
11. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.
Schuhmacher A; Reichling J; Schnitzler P
Phytomedicine; 2003; 10(6-7):504-10. PubMed ID: 13678235
[TBL] [Abstract][Full Text] [Related]
12. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations.
Bernstein DI; Ireland J; Bourne N
Antiviral Res; 2000 Sep; 47(3):159-69. PubMed ID: 10974368
[TBL] [Abstract][Full Text] [Related]
14. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol.
Sasaki K; Hayashi K; Matsuya Y; Sugimoto K; Lee JB; Kurosaki F; Hayashi T
J Nat Med; 2016 Apr; 70(2):217-24. PubMed ID: 26763002
[TBL] [Abstract][Full Text] [Related]
16. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Schneider SM; Pritchard SM; Wudiri GA; Trammell CE; Nicola AV
mBio; 2019 May; 10(3):. PubMed ID: 31088925
[TBL] [Abstract][Full Text] [Related]
17. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A
Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520
[TBL] [Abstract][Full Text] [Related]
18. The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Bridges CG; Ahmed SP; Sunkara PS; McCarthy JR; Tyms AS
Antiviral Res; 1995 Aug; 27(4):325-34. PubMed ID: 8540753
[TBL] [Abstract][Full Text] [Related]
19. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
[TBL] [Abstract][Full Text] [Related]
20. Anti-herpes simplex virus (HSV-1) activity of oxyresveratrol derived from Thai medicinal plant: mechanism of action and therapeutic efficacy on cutaneous HSV-1 infection in mice.
Chuanasa T; Phromjai J; Lipipun V; Likhitwitayawuid K; Suzuki M; Pramyothin P; Hattori M; Shiraki K
Antiviral Res; 2008 Oct; 80(1):62-70. PubMed ID: 18565600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
